Surgery Partners, Inc.
NASDAQ:SGRY
31 (USD) • At close September 13, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 2,743.3 | 2,539.3 | 2,225.1 | 1,860.1 | 1,831.4 | 1,771.456 | 1,341.219 | 1,145.438 | 959.891 | 403.289 | 284.599 | 260.215 |
| Cost of Revenue
| 2,213.9 | 1,964.4 | 1,733.7 | 1,480.3 | 1,407.6 | 1,361.431 | 1,013.8 | 821.196 | 669.326 | 254.178 | 169.844 | 159.346 |
| Gross Profit
| 529.4 | 574.9 | 491.4 | 379.8 | 423.8 | 410.025 | 327.419 | 324.242 | 290.565 | 149.111 | 114.755 | 100.869 |
| Gross Profit Ratio
| 0.193 | 0.226 | 0.221 | 0.204 | 0.231 | 0.231 | 0.244 | 0.283 | 0.303 | 0.37 | 0.403 | 0.388 |
| Reseach & Development Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 120.9 | 102.2 | 104 | 97.1 | 88.6 | 93.558 | 75.95 | 60.246 | 55.992 | 31.452 | 26.339 | 25.263 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 120.9 | 102.2 | 104 | 97.1 | 88.6 | 93.558 | 75.95 | 60.246 | 55.992 | 31.452 | 26.339 | 25.263 |
| Other Expenses
| 6.4 | 112.4 | 60.9 | 48.6 | 75.1 | 63.672 | 25.329 | -3.733 | -119.911 | 21.208 | 17.845 | 14.321 |
| Operating Expenses
| 120.9 | 214.6 | 164.9 | 145.7 | 163.7 | 157.23 | 156.368 | 123.656 | 111.829 | 52.66 | 44.184 | 39.584 |
| Operating Income
| 408.5 | 345.2 | 302.2 | 246.6 | 235.9 | 77.838 | 158.234 | 196.482 | 144.754 | 50.807 | 58.226 | 60.453 |
| Operating Income Ratio
| 0.149 | 0.136 | 0.136 | 0.133 | 0.129 | 0.044 | 0.118 | 0.172 | 0.151 | 0.126 | 0.205 | 0.232 |
| Total Other Income Expenses Net
| -273.5 | -234.9 | -221 | -265.4 | -181.3 | -174.957 | 28.904 | -7.837 | -153.893 | -45.644 | -12.345 | -0.832 |
| Income Before Tax
| 135 | 110.3 | 81.2 | -18.8 | 54.6 | -69.165 | 82.286 | 92.178 | -76.137 | -11.294 | 25.297 | 31.971 |
| Income Before Tax Ratio
| 0.049 | 0.043 | 0.036 | -0.01 | 0.03 | -0.039 | 0.061 | 0.08 | -0.079 | -0.028 | 0.089 | 0.123 |
| Income Tax Expense
| -0.3 | 23.3 | 10.5 | -20.1 | 8.5 | 26.461 | 53.55 | 7.095 | -148.982 | 15.758 | 7.57 | 6.11 |
| Net Income
| -11.9 | 87 | 70.7 | 1.3 | 46.1 | -205.706 | -52.985 | 9.453 | 1.429 | -65.897 | -9.062 | 1.916 |
| Net Income Ratio
| -0.004 | 0.034 | 0.032 | 0.001 | 0.025 | -0.116 | -0.04 | 0.008 | 0.001 | -0.163 | -0.032 | 0.007 |
| EPS
| -0.095 | 0.95 | 0.98 | 0.027 | 0.95 | -4.28 | -1.09 | 0.2 | 0.04 | -1.37 | -0.19 | 0.04 |
| EPS Diluted
| -0.095 | 0.95 | 0.98 | 0.027 | 0.95 | -4.28 | -1.08 | 0.2 | 0.04 | -1.37 | -0.19 | 0.04 |
| EBITDA
| 526.6 | 504.2 | 452.1 | 341.4 | 344.4 | 329.133 | 254.775 | 241.168 | 97.147 | 112.776 | 82.234 | 72.493 |
| EBITDA Ratio
| 0.192 | 0.199 | 0.203 | 0.184 | 0.188 | 0.186 | 0.19 | 0.211 | 0.101 | 0.28 | 0.289 | 0.279 |